These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 16883540)

  • 1. [Correlation between hepatic immunological markers and virus genotype in patients with chronic hepatitis C].
    Yu WH; Li WX; Zhou DQ; He JS; Dong JM; Song ZX
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Aug; 23(4):452-5. PubMed ID: 16883540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A study of some hepatic immunological markers, iron load and virus genotype in chronic hepatitis C.
    Cardoso EM; Duarte MA; Ribeiro E; Rodrigues P; Hultcrantz R; Sampaio P; Ehrlich R; Carvalho J; Fraga J; de Sousa M
    J Hepatol; 2004 Aug; 41(2):319-26. PubMed ID: 15288483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic iron overload in patients with chronic viral hepatitis: role of HFE gene mutations.
    Piperno A; Vergani A; Malosio I; Parma L; Fossati L; Ricci A; Bovo G; Boari G; Mancia G
    Hepatology; 1998 Oct; 28(4):1105-9. PubMed ID: 9755249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron deposition and progression of disease in chronic hepatitis C. Role of interface hepatitis, portal inflammation, and HFE missense mutations.
    Pirisi M; Scott CA; Avellini C; Toniutto P; Fabris C; Soardo G; Beltrami CA; Bartoli E
    Am J Clin Pathol; 2000 Apr; 113(4):546-54. PubMed ID: 10761457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HFE gene mutations prevent sustained virological response to interferon plus ribavirin in chronic hepatitis C patients with serum markers of iron overload.
    Coelho-Borges S; Cheinquer H; Cheinquer N; Krug L; Ashton-Prolla P
    Am J Gastroenterol; 2002 Jun; 97(6):1570-2. PubMed ID: 12094895
    [No Abstract]   [Full Text] [Related]  

  • 6. Complete eradication of hepatitis C virus after interferon treatment for chronic hepatitis C.
    De Mitri MS; Morsica G; Chen CH; Mele L; Baccarini P; Chianese R; Piccinini A; Lazzarin A; Pisi E
    Ital J Gastroenterol Hepatol; 1997 Jun; 29(3):255-61. PubMed ID: 9646218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Iron as comorbid factor in chronic hepatitis C].
    Erhardt A; Hauck K; Häussinger D
    Med Klin (Munich); 2003 Dec; 98(12):685-91. PubMed ID: 14685669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Semiquantitative and qualitative assessment of hepatic iron in patients with chronic viral hepatitis: relation with grading, staging and haemochromatosis mutations.
    Vergani A; Bovo G; Trombini P; Caronni N; Arosio C; Malosio I; Fossati L; Roffi L; Piperno A
    Ital J Gastroenterol Hepatol; 1999; 31(5):395-400. PubMed ID: 10470600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C.
    Bonkovsky HL; Naishadham D; Lambrecht RW; Chung RT; Hoefs JC; Nash SR; Rogers TE; Banner BF; Sterling RK; Donovan JA; Fontana RJ; Di Bisceglie AM; Ghany MG; Morishima C;
    Gastroenterology; 2006 Nov; 131(5):1440-51. PubMed ID: 17101320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HFE gene mutations, hepatic iron content, and histological severity in hepatitis C virus-induced chronic hepatitis.
    Ladero JM; Ropero P; Ortega L; Taxonera C; González FA; López-Alonso G; Briceño O; Rodríguez-Agulló JL; González L; Villegas A; Díaz-Rubio M
    Rev Esp Enferm Dig; 2003 Dec; 95(12):829-36. PubMed ID: 14972004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA class I B44 is associated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C.
    Romero-Gómez M; González-Escribano MF; Torres B; Barroso N; Montes-Cano MA; Sánchez-Muñoz D; Núñez-Roldan A; Aguilar-Reina J
    Am J Gastroenterol; 2003 Jul; 98(7):1621-6. PubMed ID: 12873589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression of hepatic histopathology in kidney transplant recipients with chronic hepatitis C virus infection and effect of immunosuppression on the course of hepatitis C virus infection.
    Korkmaz M; Fakı S; Öcal S; Harmancı Ö; Selçuk H; Haberal M
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():159-64. PubMed ID: 25894147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IFI35, mir-99a and HCV genotype to predict sustained virological response to pegylated-interferon plus ribavirin in chronic hepatitis C.
    Estrabaud E; Appourchaux K; Bièche I; Carrat F; Lapalus M; Lada O; Martinot-Peignoux M; Boyer N; Marcellin P; Vidaud M; Asselah T
    PLoS One; 2015; 10(4):e0121395. PubMed ID: 25844942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron accumulation in chronic hepatitis C: relation of hepatic iron distribution, HFE genotype, and disease course.
    Corengia C; Galimberti S; Bovo G; Vergani A; Arosio C; Mariani R; Redaelli A; Riva A; Cestari C; Pozzi M; Valsecchi MG; Piperno A
    Am J Clin Pathol; 2005 Dec; 124(6):846-53. PubMed ID: 16416733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C, iron status, and disease severity: relationship with HFE mutations.
    Tung BY; Emond MJ; Bronner MP; Raaka SD; Cotler SJ; Kowdley KV
    Gastroenterology; 2003 Feb; 124(2):318-26. PubMed ID: 12557137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis.
    Petit JM; Benichou M; Duvillard L; Jooste V; Bour JB; Minello A; Verges B; Brun JM; Gambert P; Hillon P
    Am J Gastroenterol; 2003 May; 98(5):1150-4. PubMed ID: 12809841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C.
    Radkowski M; Gallegos-Orozco JF; Jablonska J; Colby TV; Walewska-Zielecka B; Kubicka J; Wilkinson J; Adair D; Rakela J; Laskus T
    Hepatology; 2005 Jan; 41(1):106-14. PubMed ID: 15619235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemochromatosis gene mutations in chronic hepatitis C patients with and without liver siderosis.
    Negro F; Samii K; Rubbia-Brandt L; Quadri R; Male PJ; Zarski JP; Baud M; Giostra E; Beris P; Hadengue A
    J Med Virol; 2000 Jan; 60(1):21-7. PubMed ID: 10568758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection.
    Aghemo A; Rumi MG; Soffredini R; D'Ambrosio R; Ronchi G; Del Ninno E; Gallus S; Colombo M
    Antivir Ther; 2006; 11(6):797-802. PubMed ID: 17310824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1.
    Walsh MJ; Jonsson JR; Richardson MM; Lipka GM; Purdie DM; Clouston AD; Powell EE
    Gut; 2006 Apr; 55(4):529-35. PubMed ID: 16299039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.